Amazing Ideas On Congressional Health Reform In The United States
We have heard in recent times from many of the larger pharmaceutical companies, who tell us how they predict pharmaceutical marketing will change as we go forward. The United States Congress is pushing these companies to tell them how much they pay healthcare professionals as part of their marketing initiatives, during the process of selling their wares. It appears that key doctors have been taken on as consultants, with the aim of telling a particular story about specific products and their benefits; the full scale of these engagements is now apparent.
On the orders of Congress, pharmaceutical companies must now reveal what gifts, fees or payments they make to medical practitioners, hospitals and doctors, starting in 2012. The government will add all this information together and reveal it to the public the following year. Some organisations are choosing to pre-empt this requirement, by making information public already. Pharmaceutical sales companies defend these payments as important and indeed essential in helping to spread the word about the benefits associated with individual products. Payments are made to benefit patient care ultimately, although it is true to say that there is a certain layer of negative perception on the part of the ultimate consumer. A lot of work needs to be done and the pharmaceutical marketing and sales industry must provide a clearer and more distinct picture for the public.
Changes in the healthcare field dictate that executives and pharmaceutical consultants must pay more and more attention to sales and marketing and specific pharma training. Whether direct payments are part of an association or not, key account management training must ensure that both parties to the arrangement are clearly focused and understand the depth and breadth of the association. In certain circumstances, due to legislation, changes in the industry and varying public opinion, the position of the relationship may have to be revised. At the very least, changes dictate that key account management training must focus on the dynamic and be right on the mark for best efficiency.
Many doctors concur with the findings of pharmaceutical companies and make sure that ethical boundaries are not crossed. When they are in discussion with others, doctors make a point of revealing that they have a relationship with these companies and go out of their way to make sure that they’re not being seen as partisan.
The result of the turmoil is likely to ensure that direct payments become far less important in the overall marketing mix, especially as new reporting requirements are established. Some perceive any change as a challenge, while pharmaceutical companies that pay constant attention to the marketing mix, to the way that they treat their key account management, will always be ready to apply change for the good.
There are many external forces involved in this business, as pharmaceutical consultants well know and they are also aware that political developments can change public perception. They will ensure that pharma training keeps up with differing trends and requirements and further ensures that staff are ready to be proactive in a new field of operations. The role of the consultant is to make sure that the organisation is always ready for anything that may be posed as a challenge.
Alan Gillies is the Managing Director of L2L Consulting, specialising in enabling pharmaceutical companies to achieve new heights of productivity and performance, throughout all levels of management and revenue generating activities.
